On this page we will introduce you the members of the scientific board of the project and the team members.
Radislav Sedláček is one of the leading experts in the field of transgenic and gene-modified organisms, especially geneticaly modified mouse models. R. Sedlacek came to the Institute of Molecular Genetics after long-term foreign residence and his main task was to establish transgenic technology in the Czech Republic so that we are not dependent only on foreign workplaces.
Professor Milan Macek Jr. MD, DSc is the chairman of the Department of Biolog and Medical Genetics at the Charles University in Prague – the largest academic medical and molecular genetics institution in the Czech Republic, which also comprises a research and diagnostics reproductive genetics centre. He is also the past President of the European Society of Human Genetics (ESHG), board member of the European Society for Human Reproduction and Embryology and of the European Cystic Fibrosis Society (ECFS). His institute contributes to dissemination of knowledge in genetics gathered within various international European projects, such as CF Network, EuroGentest, EuroCareCF or Techgene, to Central and Eastern Europe.
Prof. Macek did his postdocs at the Institut of Human Genetics in Berlin and at the McKusick-Nathans Centre for Genetic Medicine, Johns Hopkins University in Baltimore. During that time he was also a fellow at Harvard School of Medicine in Boston. He hosted the 1995 HUGO Mutation Detection Course in Brno as well as the 2005 European Society of Human Genetics conference and of the 2008 European Cystic Fibrosis Conference, both held in Prague. Prof. Macek is national coordinator of Orphanet, active member of Eurogentest, has been the chief advisor of the Czech EU Council Presidency under which the “EU Council recommendation on an action in the field of rare diseases“was adopted in June 2009. He also serves at the EUCERD committee on rare diseases and is involved in the rare disease-focused initiatives EURenOmics and RD-Action.
Jiří Forejt ve svém výzkumu využívá myší genom jako model pro poznání zákonitostí vzniku nových druhů a pro studium dědičnosti lidského vývoje a lidských chorob. Myší inbrední kmeny PWD/Ph a PWK/Ph, které vznikly v jeho laboratoři před více než 30 lety, jsou užívány v genetických laboratořích zemí čtyř kontinentů a jeho chromozomální substituční kmeny, převzaté referenční The Jackson Laboratory v USA, slouží jako biomedicínský model pro systémovou genetiku.